

Electronically Filed

<b>COMMUNICATION REGARDING CO-PENDING APPLICATION</b>  <b>STATEMENT UNDER 37 C.F.R. §§1.56 AND 1.2</b>  Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	UCSF-400CIP
	Confirmation No.	5306
	First Named Inventor	Marks, James D.
	Application Number	10/632,706
	Filing Date	August 1, 2003
	Group Art Unit	1645
	Examiner Name	Minnifield, Nita M.
	TITLE: "THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS"	

Sir:

This communication is to advise the Examiner of a co-pending application in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (see also MPEP §2001.06(b)) as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897; 82 USPQ2d 1865 (Fed. Cir. 2007).

The Applicants wish to bring to the Examiner's attention co-pending U.S. Patent Application No. 11/342,271, filed January 26, 2006.

The file history and associated documents are available on PAIR, and thus are not provided with this communication.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: November 19, 2008

By: /Carol L. Francis, Reg.No.36513/  
Carol L. Francis, Ph.D.  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
235 Montgomery St. 29th Floor  
San Francisco, California 94104  
Telephone: (415) 230-8100  
Facsimile: (415) 230-5131  
F:\DOCUMENT\UCSF\400CIP\McKesson\_stmt.doc